Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma
Cells · 20.05.2024 · 13 (10) · 879
DOI: 10.3390/cells13100879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 20.05.2024. Verfasst von Anna Luise Grab und 14 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg Myeloma Center, Department of Medicine V, Medical Faculty Heidelberg and University Hospital, Heidelberg University, Im Neuenheimer Feld 4…. Hauptthemen laut MEDLINE: ADP-ribosyl Cyclase 1, Antibodies, Bispecific, Multiple Myeloma, T-Lymphocytes. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Flagship initiative for engineering molecular systems, University Heidelberg, Germany, Sanofi, Excellence Strategy of the Flagship Initiative Engineering Molecular Systems (University Heidelberg, Germany).
Abstract (Originalsprache)
Current treatment strategies for multiple myeloma (MM) are highly effective, but most patients develop relapsed/refractory disease (RRMM). The anti-CD38/CD3xCD28 trispecific antibody SAR442257 targets CD38 and CD28 on MM cells and co-stimulates CD3 and CD28 on T cells (TCs). We evaluated different key aspects such as MM cells and T cells avidity interaction, tumor killing, and biomarkers for drug potency in three distinct cohorts of RRMM patients. We found that a significantly higher proportion of RRMM patients (86%) exhibited aberrant co-expression of CD28 compared to newly diagnosed MM (NDMM) patients (19%). Furthermore, SAR442257 mediated significantly higher TC activation, resulting in enhanced MM killing compared to bispecific functional knockout controls for all relapse cohorts (Pearson’s r = 0.7). Finally, patients refractory to anti-CD38 therapy had higher levels of TGF-β (up to 20-fold) compared to other cohorts. This can limit the activity of SAR442257. Vactoserib, a TGF-β inhibitor, was able to mitigate this effect and restore sensitivity to SAR442257 in these experiments. In conclusion, SAR442257 has high potential for enhancing TC cytotoxicity by co-targeting CD38 and CD28 on MM and CD3/CD28 on T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heidelberg Myeloma Center, Department of Medicine V, Medical Faculty Heidelberg and University Hospital, Heidelberg University, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
- Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Sanofi Research and Development, Sanofi North America, Cambridge, MA 02141, USA.
- LUMICKS, 1059 CM Amsterdam, The Netherlands.
- GMMG Central Study Lab, Biobank, University Hospital Heidelberg, 69120 Heidelberg, Germany.
ORCID-Profile: Lukas John, Irene Sarkar, Philipp Reichert
Förderung
- Flagship initiative for engineering molecular systems, University Heidelberg, Germany
- Sanofi
- Excellence Strategy of the Flagship Initiative Engineering Molecular Systems (University Heidelberg, Germany)
- Dietmar-Hopp Foundation
Zitieren
APA
Grab, A. L., Kim, P. S., John, L., Bisht, K., Wang, H., Baumann, A., Van de Velde, H., Sarkar, I., Shome, D., Reichert, P., Manta, C., Gryzik, S., Reijmers, R. M., Weinhold, N., & Raab, M. S. (2024). Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma. Cells, 13(10), 879. https://doi.org/10.3390/cells13100879
Vancouver
Grab AL, Kim PS, John L, Bisht K, Wang H, Baumann A, et al. Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma. Cells. 2024;13(10):879. doi:10.3390/cells13100879
BibTeX
@article{Grab2024,
author = {Grab, Anna Luise and Kim, Peter S and John, Lukas and Bisht, Kamlesh and Wang, Hongfang and Baumann, Anja and Van de Velde, Helgi and Sarkar, Irene and Shome, Debarati and Reichert, Philipp and Manta, Calin and Gryzik, Stefanie and Reijmers, Rogier M and Weinhold, Niels and Raab, Marc S},
title = {Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma},
journal = {Cells},
year = {2024},
volume = {13},
number = {10},
pages = {879},
doi = {10.3390/cells13100879}
}
EUVIMED